MX2023006370A - Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada. - Google Patents
Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.Info
- Publication number
- MX2023006370A MX2023006370A MX2023006370A MX2023006370A MX2023006370A MX 2023006370 A MX2023006370 A MX 2023006370A MX 2023006370 A MX2023006370 A MX 2023006370A MX 2023006370 A MX2023006370 A MX 2023006370A MX 2023006370 A MX2023006370 A MX 2023006370A
- Authority
- MX
- Mexico
- Prior art keywords
- extended release
- dosing regimens
- injectable formulations
- regimens associated
- release paliperidone
- Prior art date
Links
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 title 1
- 238000013265 extended release Methods 0.000 title 1
- 239000007972 injectable composition Substances 0.000 title 1
- 229960001057 paliperidone Drugs 0.000 title 1
- VOMKSBFLAZZBOW-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-9-yl hexadecanoate Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC3=C(C)N=C4N(C3=O)CCCC4OC(=O)CCCCCCCCCCCCCCC)=NOC2=C1 VOMKSBFLAZZBOW-UHFFFAOYSA-N 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960000635 paliperidone palmitate Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona un método para tratar pacientes con formulaciones de palmitato de paliperidona inyectable de acción prolongada.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063119382P | 2020-11-30 | 2020-11-30 | |
| PCT/EP2021/062144 WO2022111858A1 (en) | 2020-11-30 | 2021-05-07 | Dosing regimens associated with extended release paliperidone injectable formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023006370A true MX2023006370A (es) | 2023-08-07 |
Family
ID=75888042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006370A MX2023006370A (es) | 2020-11-30 | 2021-05-07 | Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada. |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11324751B1 (es) |
| EP (2) | EP4025187B1 (es) |
| JP (1) | JP2023552149A (es) |
| KR (1) | KR20230116837A (es) |
| CN (1) | CN116507320A (es) |
| AU (2) | AU2021387679B2 (es) |
| CA (1) | CA3203448A1 (es) |
| DK (1) | DK4025187T3 (es) |
| ES (1) | ES2974822T3 (es) |
| FI (1) | FI4025187T3 (es) |
| HR (1) | HRP20240086T1 (es) |
| HU (1) | HUE065387T2 (es) |
| IL (1) | IL303251A (es) |
| LT (1) | LT4025187T (es) |
| MX (1) | MX2023006370A (es) |
| PL (1) | PL4025187T3 (es) |
| PT (1) | PT4025187T (es) |
| RS (1) | RS65133B1 (es) |
| SI (1) | SI4025187T1 (es) |
| TW (1) | TWI838623B (es) |
| WO (1) | WO2022111858A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230116008A (ko) | 2020-11-30 | 2023-08-03 | 얀센 파마슈티카 엔.브이. | 팔리페리돈 팔미테이트 제형의 재현탁을 보장하는 방법 |
| AU2022337993A1 (en) * | 2021-08-30 | 2024-04-11 | Janssen Pharmaceutica Nv | Dosing regimens associated with extended release paliperidone injectable formulations |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5158952A (en) | 1988-11-07 | 1992-10-27 | Janssen Pharmaceutica N.V. | 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use |
| US5254556A (en) | 1988-11-07 | 1993-10-19 | Janssen Pharmaceutica N.V. | 3-piperidinyl-1,2-benzisoxazoles |
| TW487572B (en) | 1996-05-20 | 2002-05-21 | Janssen Pharmaceutica Nv | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
| UA72189C2 (uk) | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
| JP5249748B2 (ja) | 2005-04-25 | 2013-07-31 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 無菌３−［２−［４−（６−フルオロ−１，２−ベンズイソオキサゾール−３−イル）−１−ピペリジニル］エチル］−６，７，８，９−テトラヒドロ−９−ヒドロキシ−２−メチル−４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オンパルミチン酸エステルの製造 |
| BRPI0821408A2 (pt) | 2007-12-19 | 2015-06-16 | Janssen Pharmaceutica Nv | Regime de dosagem associado a ésteres de paliperidona injetáveis de longa ação |
| US8758780B2 (en) | 2009-10-06 | 2014-06-24 | Ascendis Pharma As | Subcutaneous paliperidone composition |
| EP2493473A1 (en) | 2009-10-30 | 2012-09-05 | Janssen Pharmaceutica NV | Dosing regimen associated with long-acting injectable paliperidone esters |
| ES2456917T3 (es) | 2011-05-31 | 2014-04-24 | Laboratorios Farmacéuticos Rovi, S.A. | Formulación de implante de paliperidona |
| WO2016157061A1 (en) | 2015-03-31 | 2016-10-06 | Wockhardt Limited | Aseptic wet milling process for paliperidone palmitate |
| HUE049485T2 (hu) * | 2015-04-07 | 2020-09-28 | Janssen Pharmaceuticals Inc | Adagolási rend hosszan ható, injektálható paliperidon-észterek beadásának elmaradása esetén |
| EP3723760A4 (en) * | 2017-12-14 | 2021-10-13 | SpecGx LLC | ONE-STEP GRINDING PROCESS TO PREPARE MICRONIZED PALIPERIDONE ESTERS |
-
2021
- 2021-05-07 SI SI202130112T patent/SI4025187T1/sl unknown
- 2021-05-07 CN CN202180080436.4A patent/CN116507320A/zh active Pending
- 2021-05-07 PT PT217246511T patent/PT4025187T/pt unknown
- 2021-05-07 EP EP21724651.1A patent/EP4025187B1/en active Active
- 2021-05-07 JP JP2023532443A patent/JP2023552149A/ja active Pending
- 2021-05-07 LT LTEPPCT/EP2021/062144T patent/LT4025187T/lt unknown
- 2021-05-07 HR HRP20240086TT patent/HRP20240086T1/hr unknown
- 2021-05-07 AU AU2021387679A patent/AU2021387679B2/en active Active
- 2021-05-07 PL PL21724651.1T patent/PL4025187T3/pl unknown
- 2021-05-07 TW TW110116513A patent/TWI838623B/zh active
- 2021-05-07 MX MX2023006370A patent/MX2023006370A/es unknown
- 2021-05-07 DK DK21724651.1T patent/DK4025187T3/da active
- 2021-05-07 US US17/314,281 patent/US11324751B1/en active Active
- 2021-05-07 ES ES21724651T patent/ES2974822T3/es active Active
- 2021-05-07 FI FIEP21724651.1T patent/FI4025187T3/fi active
- 2021-05-07 KR KR1020237021416A patent/KR20230116837A/ko not_active Application Discontinuation
- 2021-05-07 CA CA3203448A patent/CA3203448A1/en active Pending
- 2021-05-07 RS RS20240087A patent/RS65133B1/sr unknown
- 2021-05-07 WO PCT/EP2021/062144 patent/WO2022111858A1/en active Application Filing
- 2021-05-07 IL IL303251A patent/IL303251A/en unknown
- 2021-05-07 HU HUE21724651A patent/HUE065387T2/hu unknown
- 2021-05-07 EP EP23219073.6A patent/EP4385564A2/en active Pending
-
2022
- 2022-05-06 US US17/738,422 patent/US20230105276A1/en active Pending
-
2024
- 2024-04-10 AU AU2024202306A patent/AU2024202306A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT4025187T (pt) | 2024-02-28 |
| RS65133B1 (sr) | 2024-02-29 |
| SI4025187T1 (sl) | 2024-03-29 |
| HUE065387T2 (hu) | 2024-05-28 |
| EP4385564A2 (en) | 2024-06-19 |
| AU2021387679B2 (en) | 2024-01-18 |
| FI4025187T3 (fi) | 2024-02-13 |
| TWI838623B (zh) | 2024-04-11 |
| CN116507320A (zh) | 2023-07-28 |
| IL303251A (en) | 2023-07-01 |
| US20220168306A1 (en) | 2022-06-02 |
| LT4025187T (lt) | 2024-02-12 |
| WO2022111858A1 (en) | 2022-06-02 |
| JP2023552149A (ja) | 2023-12-14 |
| EP4025187B1 (en) | 2024-01-03 |
| CA3203448A1 (en) | 2022-06-02 |
| ES2974822T3 (es) | 2024-07-01 |
| HRP20240086T1 (hr) | 2024-03-29 |
| TW202222318A (zh) | 2022-06-16 |
| US20230105276A1 (en) | 2023-04-06 |
| EP4025187A1 (en) | 2022-07-13 |
| PL4025187T3 (pl) | 2024-04-29 |
| AU2024202306A1 (en) | 2024-05-02 |
| KR20230116837A (ko) | 2023-08-04 |
| DK4025187T3 (da) | 2024-03-04 |
| US11324751B1 (en) | 2022-05-10 |
| AU2021387679A1 (en) | 2023-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020005651A (es) | Receptor de antigeno quimerico dirigido a bcma y usos del mismo. | |
| CL2019001292A1 (es) | Nuevos derivados de quinolina. | |
| CL2020000301A1 (es) | Nuevos derivados de quinolina. | |
| MX2019008207A (es) | Métodos para tratar el cáncer con anticuerpos anti-pd-1. | |
| MX2019008208A (es) | Métodos para tratar el cáncer con anticuerpos anti-tim-3. | |
| PH12017502079A1 (en) | Treatment of beta-thalassemia using actrii ligand traps | |
| CO6300949A2 (es) | Regimen de dosificacion asociado con esteres de paliperidona inyectables de accion prolongada | |
| CY1116424T1 (el) | Παραγωγο αδενινης ως αναστολεας ρι3κ | |
| BR112017000470A2 (pt) | composto, composição farmacêutica, método para modular atividade, método para tratar uma afecção | |
| MX2017014192A (es) | Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa. | |
| CY1122469T1 (el) | Υπογλωσσια φαρμακοτεχνικη μορφη ριλουζολης | |
| MX2023006370A (es) | Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada. | |
| MX2017008386A (es) | Administración específica del sitio de un inhibidor de btk. | |
| TW201713341A (en) | Compositions and methods of treating a neurodegenerative disease | |
| EA201791227A1 (ru) | РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM | |
| MX2018004664A (es) | Antagonistas de ep4. | |
| EA201992612A1 (ru) | Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза | |
| CL2019003078A1 (es) | Nuevos derivados de pirazol bicíclicos. | |
| BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| MY194576A (en) | Methods for the treatment of recurrent glioblastoma (rgbm) | |
| IL282538A (en) | Methods for manufacturing therapeutic delivery platforms | |
| MX2022000746A (es) | Dimetilfumarato y regimenes de vacunacion. | |
| CL2021000529A1 (es) | Administración prolongada de lasmiditan por la noche para la prevención de la migraña | |
| MX2023006366A (es) | Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada. |